Type 1 Diabetes

In this episode, Isaacs and Bellini sit down with Dawn Noe, RDN, LD, for a discussion surrounding her journey into diabetes care, the importance of individualizing nutrition in diabetes management, and the sessions she led and moderated at ADCES 2023.

Early rapid weight gain after diagnosis of T1D may play a role in the lack of remission and shorter duration of partial remission, potentially due to altered insulin sensitivity.

In this episode, which is the first of multiple special edition ADCES 2023 episodes, hosts hold an overarching discussion of the meeting itself and major themes from the ADCES's 50th anniversary celebration.

Egils K. Bogdanovics, MD, and the expert panel review the TN10 study data on the efficacy of teplizumab in delaying the progression of T1D, which led to the drug’s approval from the FDA.

Justin M. Gregory, MD, MSCI, provides an overview of the mechanism of action of teplizumab and its use in delaying T1D.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

In a Q&A, Clipper Young, PharmD, MPH, discusses the Pharm2Home Initiative based on his presentation from ADCES 2023 and describes the impact of community-driven, pharmacist-led interventions to improve health literacy in those with chronic disease.

Joshua Neumiller, PharmD, takes part in a Q&A on the role of deprescribing in older adults with diabetes mellitus based on a presentation from the Association of Diabetes Care and Education Specialists 2023 annual meeting.

Egils K. Bogdanovics, MD, and Schafer Boeder, MD, discuss interpreting antibody test results for type 1 diabetes and provide recommendations for retesting for those who have a negative test or have only 1 antibody present.

Linda A. DiMeglio, MD, reviews screening options for patients with a family history of T1D, highlighting TrialNet.

At ADCES 2023, Halis Akturk, MD, presented data calling attention to the risk of hyperglycemic ketosis-cannabis hyperemesis syndrome in people with type 1 diabetes.

An analysis of real-world data provides an overview of the effects of GLP-1 receptor agonist and SGLT2 inhibitor use among adults with type 1 diabetes.

This endocrine case report feature a woman with a history of diabetes, hypertension, and marijuana use in her mid 50s brought to the ED for confusion by her friend and neighbor who states that she has been like this for 3 days. Can you determine how best to proceed?

Expert endocrinologists discuss the clinical symptoms that prompt testing for T1D, as well the diagnostic testing tools that are available in clinical practice.

Justin M. Gregory, MD, MSC, reviews the risk factors of T1D, highlighting a family history of T1D and antibody screening.

Our July 2023 endocrinology month in review features an FDA approval, topline results from a pair of major trials, and a pair of new guidelines related to the management and diagnosis of diabetes.

Linda A. DiMeglio, MD, comments on the importance of early diagnosis of T1D, giving patients the advantage of preparing a treatment plan early.

Expert endocrinologists review the importance of staging and classifying T1D, highlighting dysglycemia.

The American Diabetes Association, together with the American Association of Clinical Chemistry, has released a new, 49-page document outlining optimized guidance for use of laboratory analysis in the diagnosis and management of diabetes.

However, the analysis suggests young adults with T2D who underwent vitrectomy for PDR had worse final visual acuity and more complications compared to those with T1D.

Justin M. Gregory, MD, MSC, and Linda A. DiMeglio, MD, provide an overview of the pathophysiology of type 1 diabetes.

Schafer Boeder, MD, discusses the incidence of type 1 diabetes, highlighting risk factors such as age and family history.

An analysis of EHR data recorded from 2018-2022 within Duke University Medical Center-affiliated diabetes care centers suggests the increased rate of new-onset type 1 and type 2 diabetes observed during the first year of the pandemic persisted through 2022.

Women with type 1 diabetes experience a three times greater risk of sexual dysfunction than women without diabetes.

Fear of hypoglycemia is associated with negative outcomes in people with T1D that may influence psychosocial well-being and diabetes management.